WO2021072595A1 - Utilisation médicale de cellules souches mésenchymateuses dans le traitement d'une déficience auditive - Google Patents

Utilisation médicale de cellules souches mésenchymateuses dans le traitement d'une déficience auditive Download PDF

Info

Publication number
WO2021072595A1
WO2021072595A1 PCT/CN2019/111034 CN2019111034W WO2021072595A1 WO 2021072595 A1 WO2021072595 A1 WO 2021072595A1 CN 2019111034 W CN2019111034 W CN 2019111034W WO 2021072595 A1 WO2021072595 A1 WO 2021072595A1
Authority
WO
WIPO (PCT)
Prior art keywords
mesenchymal stem
hearing impairment
stem cells
hearing
cells
Prior art date
Application number
PCT/CN2019/111034
Other languages
English (en)
Chinese (zh)
Inventor
许益超
黄美月
陈彦聪
蔡宏逸
Original Assignee
玛旺干细胞医学生物科技股份有限公司
许益超
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 玛旺干细胞医学生物科技股份有限公司, 许益超 filed Critical 玛旺干细胞医学生物科技股份有限公司
Priority to PCT/CN2019/111034 priority Critical patent/WO2021072595A1/fr
Publication of WO2021072595A1 publication Critical patent/WO2021072595A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • This application relates to the medical use of mesenchymal stem cells, especially the medical use of human skin mesenchymal stem cells in the treatment of hearing disorders.
  • the process of auditory perception is basically to first make the sound pass through the auricle of the outer ear, the outer auditory canal to the eardrum, and then to the three ossicles located in the middle ear cavity, and then enter the inner ear through the oval window, and from the inner ear located on the cochlear basement membrane.
  • Inner hair cells convert sound signals into nerve signals, which pass through the auditory nerve and brainstem, and finally reach the auditory area of the brain to produce hearing.
  • a problem at any point in this path may cause hearing impairment.
  • Hearing disorders can be caused by many different causes, including genetic defects, aging, noise damage, pathogenic microbial infections, childbirth complications, ear trauma, drug or poison damage, etc.
  • hearing impairment can be divided into five types: (1) Conductive hearing impairment: occurs in the outer or middle ear.
  • the causes include cerumen embolism, foreign body, inflammation, tympanic membrane perforation, middle ear effusion, and ossicles.
  • Rupture or dislocation, etc. usually belong to mild to moderate hearing impairment, which can be improved by drugs or surgery;
  • Sensorineural hearing impairment it occurs in the inner ear or auditory nerve, usually because the auditory hair cells in the cochlea are damaged Or it is caused by lack of it.
  • the etiology includes viral infection, ototoxic drug poisoning, aging, noise damage, etc.
  • Patients suffering from this type of hearing impairment are usually less sensitive to high-frequency sounds; (3) Mixed hearing impairment, patients are combined Suffering from conductive hearing impairment and sensorineural hearing impairment; (4) Central hearing impairment, which occurs in the central auditory nervous system, and causes include aging, brain injury, neuropathy, etc.; and (5) Functional hearing impairment, patients No organic disease on the auditory canal occurred, but due to psychological or emotional factors, the sensitivity to sound decreased.
  • platinum-containing chemotherapeutic drugs are widely used to treat sarcomas, malignant epithelial tumors, lymphoma and germ cell tumors, such as head and neck cancer, brain tumors, ovarian cancer, bladder cancer, and non-small cell lung cancer.
  • cisplatin is used (cisplatin; cis-dichlorodiammine platinum (II)) is the most representative.
  • a serious side effect of this type of chemotherapeutic drugs is ototoxicity, which significantly reduces the quality of life of cancer patients.
  • the ototoxicity of cisplatin mainly occurs in the cochlea and is generally believed to be related to the production of reactive oxygen species.
  • Cisplatin is absorbed by stria vascularis, cochlear fluid, and hair cells to enter the cochlea tissue, which activates the third isomer of NADPH oxidase and increases the content of reactive oxygen species in the cochlea.
  • endogenous antioxidants such as glutathione
  • NF ⁇ B transcription factor
  • MSCs Mesenchymal stem cells
  • mesenchymal stem cells have the ability of cell proliferation and multidirectional differentiation, and can differentiate into chondrocytes, adipocytes, sclerocytes, etc.
  • mesenchymal stem cells have the function of repairing and replacing damaged neurons, they have been actively used in the development of treatments for brain trauma, stroke and neurodegenerative diseases (Hosseini et al., Int J Stem Cells 8:191 -9; and Yoo SW et al., Exp Mol Med 40:387-97).
  • mesenchymal stem cells also have the properties of regulating human immune function and reducing cell oxidative stress. Through the action of exocrine microvesicles, it can regulate the imbalance between immune function and oxidative stress in the body.
  • mesenchymal stem cells especially human mesenchymal stem cells, such as human skin mesenchymal stem cells, can effectively improve this animal model of hearing impairment.
  • the disclosure of this application shows that mesenchymal stem cells can bring beneficial effects on hearing impairment, and can be used as an alternative or supplementary medicine for the treatment of hearing impairment.
  • the present invention provides a use of a mesenchymal stem cell composition in the preparation of a medicament for the treatment of hearing disorders in an individual, wherein the mesenchymal stem cell composition comprises mesenchymal stem cells And a pharmaceutically acceptable carrier.
  • a method for treating hearing impairment in an individual comprising administering to the individual an effective amount of a mesenchymal stem cell composition; wherein the mesenchymal stem cell composition comprises Mesenchymal stem cells and pharmaceutically acceptable carriers.
  • the mesenchymal stem cells are skin mesenchymal stem cells.
  • the mesenchymal stem cells are derived from humans.
  • the mesenchymal stem cells are human skin mesenchymal stem cells.
  • the hearing impairment is selected from sensorineural hearing impairment, mixed hearing impairment and central hearing impairment. In a more preferred embodiment, the hearing impairment is selected from sensorineural hearing impairment.
  • the sensorineural hearing impairment is caused by ototoxic drugs.
  • the ototoxic drug is selected from platinum-containing chemotherapeutic drugs.
  • the platinum-containing chemotherapeutic drug is selected from cisplatin.
  • the individual is a human.
  • the mesenchymal stem cell composition is prepared as an injection form of a sterile liquid solution or suspension.
  • Figure 1 is the process of establishing a mouse model of hearing impairment, showing that cisplatin was injected through the abdominal cavity every day from day 0 to day 5, and human skin mesenchymal stem cells were injected through the tail vein on day 8;
  • Figure 2 is a bar graph showing the performance of each group of mouse models in the auditory brainstem response (ABR) test.
  • Fig. 3 is a photograph of tissue analysis after immunofluorescence staining, showing the condition of hair cells in the cochlea tissue of each group of mouse models.
  • MSCs multipotent stem cells derived from adult stromal tissues. These adult stromal tissues include but are not limited to bone marrow, umbilical cord, amniotic membrane, Amniotic fluid, adipose tissue, pulp cavity, skeletal muscle and skin. MSCs have the ability to self-renew and have the ability to differentiate into cells of the mesenchymal cell lineage.
  • the MSC used in this application can be collected from humans, rats, mice, sheep, cows, pigs, dogs, cats, horses, and non-human primates (such as monkeys, gorillas, and chimpanzees).
  • the MSCs are derived from humans.
  • the MSCs used in this application are isolated from the skin, namely skin mesenchymal stem cells (SMSCs).
  • SMSCs skin mesenchymal stem cells
  • the skin mesenchymal stem cells are human skin mesenchymal stem cells.
  • MSCs from the 1st to 10th generations are usually used, and MSCs from the 2nd to 6th generations are preferably used.
  • MSCs can be collected from various sources by methods known in the art, usually stem cells are isolated from tissues. Subsequently, the MSCs were incubated in an appropriate medium for a period of time, and then the supernatant was collected. For example, in the specific example of collecting SMSCs, the skin tissue is first obtained from the skin of the provider through a surgical operation, then the tissue is digested with collagenase, the cell clusters precipitated after centrifugation are washed with phosphate buffer, and then The cells were cultured in a culture medium and other cells were removed to collect SMSCs. In a preferred embodiment, the collection of MSCs can also include isolating MSCs from cell culture by using differences in surface antigen markers.
  • Non-limiting examples of isolation methods include magnetic cell sorting (MACS), fluorescence activated cell sorting (FACS), and flow cytometry sorting (FCS). If more than 95% of the collected cells have the three cell surface markers CD90, CD73 and CD105, it can be confirmed that they are human skin mesenchymal stem cells. Subsequently, the collected MSCs are cultured in an appropriate medium for at least 3 hours, preferably 3 to 120 hours, more preferably 24 to 96 hours, for example 72 to 96 hours.
  • MCS magnetic cell sorting
  • FACS fluorescence activated cell sorting
  • FCS flow cytometry sorting
  • the medium refers to any liquid medium containing in vitro culture for supporting human or animal cells.
  • the medium is a basic medium containing basic nutrients such as inorganic salts, amino acids and vitamins.
  • basal media suitable for the present invention include but are not limited to Eagle's Basic Medium (Basal Medium Eagles; BME), Minimum Essential Medium (MEM), Dubbock's Modified Eagle's Medium ( Dulbecco's Modified Eagle's Medium; DMEM), nutrient mixed medium F-10 (HAM's F-10), nutrient mixed medium F-12 (HAM's F-12), or a combination thereof. These media can be easily prepared or purchased from the market.
  • the medium is DMEM.
  • serum such as serum, plasma, and platelet-rich plasma may be added to the culture medium to support the growth of the cultured cells.
  • the medium is supplemented with serum, such as DMEM supplemented with serum.
  • serum refers to a liquid preparation derived from human or animal blood, in which blood cells, fibrinogen and fibrin are removed to provide nutrients for cell growth, especially refers to serum preparations derived from humans or animals living in non-epidemic areas, including but not limited to human serum, fetal bovine serum (FBS), calf serum, adult bovine serum or serum from other animals, such as from Serum preparation for horses and camels.
  • FBS fetal bovine serum
  • calf serum calf serum
  • adult bovine serum or serum from other animals such as from Serum preparation for horses and camels.
  • the amount of serum in the culture medium is in the range of about 0.5 to 20% by volume based on the total volume of the culture medium.
  • the cell culture medium can be further supplemented with other components, such as vitamins, proteins and sugars, growth factors (such as FGF and EGF), antibiotics (such as penicillin, streptomycin, and tetracycline), fungicides, hormones, and antioxidants Wait.
  • growth factors such as FGF and EGF
  • antibiotics such as penicillin, streptomycin, and tetracycline
  • fungicides such as penicillin, streptomycin, and tetracycline
  • the term "culture” refers to the maintenance of MSCs under in vitro conditions that are conducive to the growth and survival of MSCs.
  • the method of culturing MSCs belongs to the conventional and routine methods in the technical field involved in this application. This application uses standard methods to cultivate MSCs using aseptic processing and manipulation. Generally, the optimum temperature for culture is about 35 to 37°C.
  • the cells are cultured in a carbon dioxide incubator.
  • the carbon dioxide incubator is usually set at a constant temperature (for example, 37°C), a stable CO 2 level (for example, 5%), a constant pH (for example, pH 7.2-7.4), and a relatively high relative saturation humidity (for example, 95%), To simulate the growth environment of cells in organisms.
  • the MSCs culture can be processed by conventional means such as centrifugation or filtration to remove the aqueous part, and then trypsin is used to detach the MSCs from the attached surface, thereby harvesting the cells.
  • MSCs especially SMSCs, such as SMSCs derived from human skin tissue
  • hearing disorders have the effect of treating hearing disorders.
  • hearing impaired generally refers to an individual's decreased sensitivity to sound perception.
  • hearing impairment mainly refers to their low sensitivity to the frequency of daily speech.
  • WHO World Health Organization
  • the severity of hearing impairment can be divided into 4 levels according to the average hearing threshold at four frequencies of 500Hz, 1000Hz, 2000Hz and 4000Hz: 26-40 decibels (dB) It belongs to mild hearing impairment, 41 to 60 decibels are moderate, 61 to 80 decibels are severe, and greater than 80 decibels are depth.
  • hearing impairment can be diagnosed through hearing tests. These hearing tests include (1) behavioral or subjective hearing tests, such as pure tone audiometry, tuning fork tests, voice hearing tests, etc.; and (2) physiological or objective tests Hearing tests, such as auditory brainstem response (ABR) test, impedance audiometry, oto-acoustic emissions, etc. Additional tympanic hearing tests, computed tomography and magnetic resonance imaging can also be performed to assist specialists in diagnosis.
  • the hearing impairment includes, but is not limited to, conductive hearing impairment, sensorineural hearing impairment, mixed hearing impairment, and central hearing impairment.
  • the hearing impairment is selected from the group consisting of sensorineural hearing impairment, mixed hearing impairment and central hearing impairment.
  • the hearing disorder is selected from sensorineural hearing disorders, in particular sensorineural hearing disorders involving degeneration, injury or death of hair cells in the cochlea.
  • the damage of the hair cells can be evaluated by the histochemical analysis of Example 3 below and/or the audiograms obtained from the above-mentioned hearing examination showing the loss of sensitivity to mid- and high-frequency sounds.
  • the hearing impairment is caused by congenital genetic defects of hair cells (such as mitochondrial DNA mutations, OTOF gene mutations), acquired chemical or physical damage (such as ototoxic drug poisoning, noise Injuries), infectious pathogen infections (such as meningitis, mumps, measles, scarlet fever, influenza) or degeneration of senile sexual function (such as insufficient blood supply to hair cells due to vascular sclerosis).
  • the hearing impairment is caused by an ototoxic drug.
  • ototoxic drug refers to a drug that may cause damage to the outer hair cells and/or inner hair cells in the cochlea after administration, which includes but is not limited to (1) aminoglycoside antibiotics , Such as gentamicin, kanamycin, polymyxin, dihydrostreptomycin, neomycin, etc.; (2) anti-cancer agents, including platinum-containing chemotherapeutic drugs (such as cisplatin, carboplatin (carboplatin) ), nedaplatin, oxaliplatin, lobaplatin and miriplatin), vinblastine anticancer agents, methotrexate, etc.; (3) Antimalarial drugs, such as quinine; (4) diuretics, such as ethacrynic acid, furosemide; (5) steroids, such as corticotropin, prednisone ); (6) Non-steroidal analgesics, such as salicylic acid, diclofenac, and
  • the inventor of the present application established an animal model of hearing impairment by administering cisplatin to mice through the ototoxicity of cisplatin.
  • the present application evaluated the medical effect of MSCs on hearing impairment by administering MSCs to this animal model.
  • the auditory brainstem response test described in Example 2 and the histochemical analysis described in Example 3 below consistently show that the typical symptoms of hearing impairment caused by cisplatin, such as hearing loss and ear hair Cell damage can be improved by administering MSCs. It is worth noting that the administration of ototoxic drugs is selected as a representative hearing impairment trigger mode, because the typical hearing impairment symptoms caused by them also commonly appear in hearing impairments caused by other factors.
  • MSCs when MSCs enter the body of patients with hearing impairment, they can secrete a variety of growth factors, cytokines and chemokines, which can enhance cell survival, repair cells, and reduce inflammation. MSCs may also reduce the oxidative pressure of cells by releasing exocrine microvesicles and prevent them from going to apoptosis.
  • this application covers the medical use of MSC for the treatment of hearing impairment in an individual, and a method of treating hearing impairment in an individual, the method comprising administering an effective amount of MSC to the individual.
  • the term "individual” as used herein is intended to encompass human or non-human vertebrates, such as non-human mammals.
  • Non-human mammals include domestic animals, companion animals, laboratory animals, and non-human primates.
  • Non-human individuals also include, but are not limited to, horses, cows, pigs, goats, dogs, cats, mice, rats, guinea pigs, gerbils, hamsters, minks, and rabbits. It should be understood that the preferred individuals are humans, especially human patients suffering from or at risk of hearing impairment.
  • treatment in this specification means to reverse, alleviate, delay the onset or inhibit the progress of the mood disorders described in this specification or one or more of their symptoms.
  • treatment can be performed after one or more symptoms develop. Treatment can also be continued after the symptoms are resolved to delay its recurrence.
  • MSCs can be formulated together with a pharmaceutically acceptable carrier to prepare a mesenchymal stem cell composition suitable for administration to an individual.
  • a pharmaceutically acceptable carrier as used in this application means an inert substance used as a carrier for MSCs, which has no toxicity, irritation, pyrogenicity, antigenicity, or hemolysis to the site of application, and no The substantial pharmacological activity will not hinder the exertion of the beneficial effects of the MSCs.
  • the amount of the pharmaceutically acceptable carrier is from about 1% to about 99.9%, preferably from about 50% to about 99%, based on the total weight of the composition.
  • the suitable type of pharmaceutically acceptable carrier depends on the form of the composition.
  • MSCs can be administered to an individual by any suitable route.
  • the mesenchymal stem cell composition is prepared as an injection, which is in the form of a sterile liquid solution or suspension, to introduce MSCs into an individual's body via veins, arteries, or spinal fluid.
  • the pharmaceutically acceptable carrier is isotonic with the blood of the individual.
  • Suitable pharmaceutically acceptable carriers include, but are not limited to, water, physiological saline, balanced salt solutions (e.g., phosphate buffered physiological saline (PBS), Hank's balanced salt solution (HBSS)), vegetable oils, dextrose, glycerin , Ethanol, wetting agent, emulsifier and pH buffering agent. In some specific cases, it may be necessary to formulate the composition with a preservative (such as thimerosal or sodium azide) to facilitate long-term storage.
  • the carrier may also contain other pharmaceutically acceptable excipients for changing or maintaining the pH, osmolarity, viscosity, transparency, color, sterility, stability, dissolution rate, or odor of the composition.
  • the term "administration" includes allocating, delivering, or administering MSCs in a suitable composition to an individual by any suitable route, so as to administer the mesenchymal stem cell composition or its metabolome. It is delivered to the desired location in the individual, so that the composition or its metabolite group is brought into contact with the target cell or tissue.
  • the mesenchymal stem cell composition is administered to the individual before, during, and/or after the onset of the emotional disorder.
  • one or more therapeutic agents can be administered to the individual together with the mesenchymal stem cell composition.
  • the mesenchymal stem cell composition may be administered before the one or more therapeutic agents (e.g.
  • the mesenchymal stem cell composition and the therapeutic agent can be administered by different schedules (for example, different plans), different administration routes, or different dosages.
  • the mesenchymal stem cell composition is administered to an individual in a therapeutically effective amount to induce the biological or drug response in cells, tissues, systems, animals or humans sought by researchers, veterinarians, doctors or other clinicians, preferably stable , Improve or alleviate one or more symptoms of the disease condition in the individual, such as tinnitus, hair cell death, hearing loss or loss, ear stuffiness, intermittent sound blur, poor or distorted speech recognition, hearing hallucinations , Avoid social interaction, dizziness, and headaches. Therefore, the term "effective amount” refers to the amount of the mesenchymal stem cell composition that produces the medicinal effect of observing any of the above-mentioned symptoms when an effective amount of the composition is administered to an individual.
  • the effective amount is usually determined by comparing them with the effect observed in the absence of the mesenchymal stem cell composition disclosed herein (ie, the control group), the actual dose is calculated according to the specific route of administration selected .
  • the actual dose can be calculated according to the particular route of administration selected.
  • Those skilled in the relevant art will routinely further refine the calculations required to determine the appropriate dosage. Therefore, when administered to a human individual, it is preferably 1 ⁇ 10 4 cells/kg body weight/day to 1 ⁇ 10 7 cells/kg body weight/day per day, weekly or twice a week, for example, 5 ⁇
  • the mesenchymal stem cell composition is administered in an amount of 10 5 cells/kg body weight/day to 5 ⁇ 10 6 cells/kg body weight/day.
  • the mesenchymal stem cell composition is used for autologous cell therapy, that is, mesenchymal stem cells are obtained from an individual in advance, cultured in vitro, and then transplanted back to the same individual.
  • autologous cell therapy that is, mesenchymal stem cells are obtained from an individual in advance, cultured in vitro, and then transplanted back to the same individual.
  • autoimmune therapy has relatively few side effects, high safety, and is not prone to allergies and rejection.
  • the composition mainly consists of MSCs and the aforementioned pharmaceutically acceptable carrier.
  • the "mainly composed of” as used herein means that the described combination of components does not exclude the inclusion of other undescribed components that do not substantially affect the properties and functions of the aforementioned composition.
  • the composition of the present application only consists of MSCs and the aforementioned pharmaceutically acceptable carrier.
  • the human skin sample was cut into a size of about 3 mm 2 and transferred to an enzyme reaction solution containing neutral protease (dispase) and collagenase, and reacted at 37°C for 16 hours.
  • the skin sample fragments and the enzyme reaction solution were transferred to a centrifuge tube, and an equal volume of Dulbecco's modified Eagle's medium (DMEM; Sigma Chemical Co., St. Louis, Missouri, USA) supplemented with an appropriate amount of serum was added for enzyme neutralization. Centrifuge at 1500 rpm for 5 minutes, remove the supernatant, and add DMEM medium containing serum and antibiotics to suspend the cells and move them to a new petri dish, and place them in a carbon dioxide incubator at 37°C for culture.
  • DMEM Dulbecco's modified Eagle's medium
  • the aqueous part of the skin mesenchymal stem cell culture is removed, and the cells are washed, and then the cells are trypsinized to remove the cells from the culture container, and then the cells are suspended in an aqueous carrier for later use.
  • mice 8-week-old C57BL/6 female mice were purchased from Lesco Biotechnology Co., Ltd. (Taipei City). Animals are kept in a sterile environment with automatic 24-hour temperature and humidity control. The room temperature is maintained at 20-22°C, humidity is 50% ⁇ 5%, and the lighting cycle is 12/12 hours day and night. The animals are fed standard rodent feed. As shown in Figure 1, from day 0 to day 5, cisplatin (purchased from Sigma–Aldrich Chemical Co., St. Louis, Missouri, USA) was injected intraperitoneally every day from day 0 to day 5 at a dose of 4 mg/kg mouse body weight to establish Animal model of hearing loss. The control group was intraperitoneally injected with an equal volume of 0.25% dimethyl sulfoxide (DMSO).
  • DMSO dimethyl sulfoxide
  • the auditory brainstem response (ABR) test was used to evaluate the hearing threshold of each group of animals before the administration of cisplatin on day 0 and on the 15th day, and records were recorded The difference is the threshold offset (in decibels (dB)). The larger the threshold shift value, the more severe the hearing loss caused by cisplatin.
  • ketamine 40 mg/kg
  • xylazine 10 mg/kg
  • ABR workstation BIOPAC Systems
  • the ABR waveform is averaged in the interval of 10 milliseconds.
  • the sound intensity changes every 10 decibels around the hearing threshold. Based on ABR records, blind analysis was performed by two independent observers.
  • Figure 2 is a histogram drawn based on the average values obtained from three independent ABR tests. It shows that the mice in group (III) injected with cisplatin, whether given a series of low-frequency, intermediate-frequency, or high-frequency sound bursts, its The threshold deviation of the ABR test was higher than that of the mice injected with DMSO in group (I), and the statistical analysis reached the significance of p ⁇ 0.05. This indicates that the mice injected with cisplatin showed significant hearing loss compared to the control group, and this application successfully established an animal model of hearing loss.
  • mice in each group of Example 1 were anesthetized with isoflurane, and were first perfused with normal saline and then with paraformaldehyde phosphate buffer.
  • the cochlear tissue located in the inner ear of the animal was collected and fixed with freshly prepared 4% paraformaldehyde at 4°C for 30 minutes.
  • the cochlear tissue was embedded in a frozen tissue embedding agent, and then sliced into a thickness of 10 microns.
  • all the sections were incubated with 4',6-diamidino-2-phenylindole, multiple MYO7A antibodies, and phalloidin to display the nucleus of ear hair cells by fluorescent staining. Myosin and cytoskeleton. After washing three times with phosphate buffer, the condition of ear hair cells was observed under a laser conjugate focus microscope (model TCS-SP2; Leica Microsystems Heidelberg GmbH, Heidelberg, Germany).
  • Figure 3 shows that the ear hair cells of the mice in the group (III) injected with cisplatin showed obvious defects (as indicated by the arrow) than the ear hair cells of the mice in the group (I) injected with DMSO. This once again points out that this application has successfully established an animal model of hearing loss. Compared with the group (III), the mice (groups (IV) and (V)) that were given MSC preparations through the tail veins had significantly improved ear hair cell defects.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)

Abstract

La présente invention concerne l'utilisation médicale de cellules souches mésenchymateuses, en particulier l'utilisation médicale de cellules souches mésenchymateuses de peau humaine dans le traitement d'une déficience auditive. La déficience auditive comprend, mais n'est pas limitée à, une déficience auditive neurosensorielle, une déficience auditive mixte et une déficience auditive centrale.
PCT/CN2019/111034 2019-10-14 2019-10-14 Utilisation médicale de cellules souches mésenchymateuses dans le traitement d'une déficience auditive WO2021072595A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/111034 WO2021072595A1 (fr) 2019-10-14 2019-10-14 Utilisation médicale de cellules souches mésenchymateuses dans le traitement d'une déficience auditive

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/111034 WO2021072595A1 (fr) 2019-10-14 2019-10-14 Utilisation médicale de cellules souches mésenchymateuses dans le traitement d'une déficience auditive

Publications (1)

Publication Number Publication Date
WO2021072595A1 true WO2021072595A1 (fr) 2021-04-22

Family

ID=75537397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/111034 WO2021072595A1 (fr) 2019-10-14 2019-10-14 Utilisation médicale de cellules souches mésenchymateuses dans le traitement d'une déficience auditive

Country Status (1)

Country Link
WO (1) WO2021072595A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101215546A (zh) * 2007-12-31 2008-07-09 浙江大学 利用骨髓间充质干细胞诱导获得内耳毛细胞前体的方法
CN101878297A (zh) * 2007-07-05 2010-11-03 再生科学有限责任公司 用于间质干细胞优化扩增和移植的方法与组合物
CN104136034A (zh) * 2011-11-30 2014-11-05 先进细胞技术公司 间充质基质细胞及其相关用途
CN106520691A (zh) * 2016-12-30 2017-03-22 潍坊医学院 一种皮肤间充质干细胞的分离及培养方法
US20170189448A1 (en) * 2013-11-27 2017-07-06 Fundación Pública Andaluza Progreso Y Salud Novel mesenchymal stem cell surface marker

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101878297A (zh) * 2007-07-05 2010-11-03 再生科学有限责任公司 用于间质干细胞优化扩增和移植的方法与组合物
CN101215546A (zh) * 2007-12-31 2008-07-09 浙江大学 利用骨髓间充质干细胞诱导获得内耳毛细胞前体的方法
CN104136034A (zh) * 2011-11-30 2014-11-05 先进细胞技术公司 间充质基质细胞及其相关用途
US20170189448A1 (en) * 2013-11-27 2017-07-06 Fundación Pública Andaluza Progreso Y Salud Novel mesenchymal stem cell surface marker
CN106520691A (zh) * 2016-12-30 2017-03-22 潍坊医学院 一种皮肤间充质干细胞的分离及培养方法

Similar Documents

Publication Publication Date Title
KR102073730B1 (ko) 인간 ｒｐｅ 세포의 생산 방법 및 인간 ｒｐｅ 세포의 제약 제제
JP2009500297A (ja) 眼の変性についての細胞療法
JP2010018627A (ja) 血管の形成ならびに血管新生および栄養因子の生産に使用するための骨髄間質細胞に由来する物質
KR102019277B1 (ko) 미토콘드리아를 포함하는 허혈성 질환 예방 또는 치료용 조성물
CA2669304A1 (fr) Utilisation d'une composition comprenant des cellules souches mesenchymales extraites du sang de cordons ombilicaux et provoquant la differentiation et la proliferation de cellules neurales precurseurs ou de cellules souches neurales en cellules neurales
JP7014449B2 (ja) 神経障害を処置するための間葉系細胞由来エキソソーム
JP2010504083A (ja) 血液、特に末梢血から成体幹細胞を増殖させるための方法及び医療分野におけるその利用
JP2013528230A (ja) ノーオプション重症虚血肢（ｃｌｉ）を処置するための組成物および方法
US20230145213A1 (en) Pre-conditioned mesenchymal stem cells and preparations and applications thereof
JP2001515505A (ja) 軸索再生を促進する単核貪食細胞及びその使用
Zhang et al. Reducing host aldose reductase activity promotes neuronal differentiation of transplanted neural stem cells at spinal cord injury sites and facilitates locomotion recovery
JP2022502047A (ja) ヒト網膜前駆細胞の単離および培養の方法
TW200423951A (en) Method of preparing anti-angiogenic drug from cartilage and chondrocytes and methods of use
TW202041222A (zh) 間質幹細胞在預防和治療情緒疾病上的醫藥用途
WO2021072595A1 (fr) Utilisation médicale de cellules souches mésenchymateuses dans le traitement d'une déficience auditive
Zhou et al. Neutrophils compromise retinal pigment epithelial barrier integrity
Wiranowska et al. Evaluation of blood-brain barrier permeability and the effect of interferon in mouse glioma model
TW202113070A (zh) 間質幹細胞在治療聽力障礙上的醫藥用途
US20220145248A1 (en) Use of Adipose-Derived Stem Cells for Glaucoma Treatment
CN114099664A (zh) 一种基于Treg细胞外泌体的靶向协同药物体系及其制备方法
CN107243006B (zh) Amd3100在制备治疗和/或预防恶液质的药物中的应用
WO2020181411A1 (fr) Utilisation médicale de cellules souches mésenchymateuses pour prévenir ou traiter des troubles émotionnels
TWI690327B (zh) 西瑞香素於預防組織或器官移植排斥或是移植物抗宿主疾病之用途
US20210353682A1 (en) Pharmaceutical product for preventing or treating alzheimer's disease
US20210244773A1 (en) Dental pulp stem cells and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19949411

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19949411

Country of ref document: EP

Kind code of ref document: A1